first_img News | Neuro Imaging | July 05, 2019 Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American… read more Technology | Contrast Media | July 15, 2019 FDA Approves Bayer’s Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance… read more Related Content Feature | Contrast Media | July 18, 2019 | By Greg Freiherr How To Manage Risk in the MR Suite Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n read more Feature | May 20, 2014 GE Healthcare Partners With Tesla Engineering to Produce Ultra High-Field 7T MRI Systems Images of regions of interest (colored lines) in the white matter skeleton representation. Data from left and right anterior thalamic radiation (ATR) were averaged. Image courtesy of C. Bouziane et al. News | Magnetic Resonance Imaging (MRI) | August 06, 2019 Canon Medical Introduces Encore Orian MR Upgrade Program Canon Medical Systems USA Inc. is helping to provide low-cost patient care solutions for its customers with the launch… read more News | Focused Ultrasound Therapy | July 10, 2019 Insightec’s Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s… read more Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco Technology | Neuro Imaging | August 07, 2019 Synaptive Medical Launches Modus Plan With Automated Tractography Segmentation Synaptive Medical announced the U.S. launch and availability of Modus Plan featuring BrightMatter AutoSeg. This release… read more News | Image Guided Radiation Therapy (IGRT) | July 16, 2019 AAPM 2019 Features More Than 40 Presentations on ViewRay’s MRIdian MRI-guided Radiotherapy ViewRay Inc. announced that the company’s MRIdian System is the focus of more than 40 abstracts selected by the… read more News | Neuro Imaging | August 16, 2019 ADHD Medication May Affect Brain Development in Children A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s… read more News | Magnetic Resonance Imaging (MRI) | August 01, 2019 | Jeff Zagoudis, Associate Editor FDA Issues Draft Guidance on Medical Device Safety in MRI Environment The U.S. Food and Drug Administration (FDA) issued a new draft guidance titled Testing and Labeling Medical Devices for… read more May 20, 2014 — GE Healthcare and Tesla Engineering Ltd. are collaborating to produce 7T human whole-body magnetic resonance imaging (MRI) scanners. The companies made the announcement at the joint meeting of the International Society for Magnetic Resonance in Medicine (ISMRM) and the European Society for Magnetic Resonance in Medicine and Biology (ESMRMB) in Milan.Ultra high-field MRI systems are used for scientific and medical research, primarily for morphological and functional imaging of the brain while steadily expanding to all anatomies. Researchers using ultra high-field scanners hope their work will contribute to earlier disease detection, more accurate diagnosis and increased effectiveness of investigational therapies for disorders and diseases such as cancer, stroke, epilepsy, drug abuse, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, attention deficit disorder, multiple sclerosis, head injury, visual disorders and schizophrenia.Tesla Engineering Ltd. is currently building a new factory in Storrington, U.K., to manufacture the 7 Tesla magnets. They have recruited several key engineering and management staff with extensive experience in the design and manufacturing of ultra high-field magnets. The first unit from the new production line is committed to GE and scheduled to ship in late 2015.“This agreement will enable GE to deepen and broaden our collaborations with leading MRI academics and visionaries, sharing our collective expertise and missions in technology, science and medicine,” said Richard Hausmann, president and CEO of GE Healthcare, MR. “The GE 7T community in the U.S., Europe and Asia has already demonstrated breakthrough observations and understanding of Alzheimer’s disease, traumatic brain injury and cognitive physiology. Together, we will continue to push the frontiers of MRI for neuroscience and other applications.”“Tesla is very pleased to collaborate with GE and to take a leadership position in the continuing evolution of MR magnet technology,” said Mike Begg, group managing director, Tesla Engineering Ltd. “This is a solid business opportunity for us that complements and builds upon our existing strengths in superconducting magnet technology, as well as our strong core technology positions in cryogenics.”For more information: www.gehealthcare.com, www.tesla.co.uk FacebookTwitterLinkedInPrint分享 Technology | Interventional Radiology | August 16, 2019 Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to… read more last_img